Point72 Asia Singapore Pte. Ltd. Makes New $66,000 Investment in Cue Biopharma, Inc. (NASDAQ:CUE)

Point72 Asia Singapore Pte. Ltd. purchased a new stake in Cue Biopharma, Inc. (NASDAQ:CUE) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 53,027 shares of the company’s stock, valued at approximately $66,000.

Separately, Wedmont Private Capital raised its holdings in Cue Biopharma by 100.0% in the 1st quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock valued at $76,000 after acquiring an additional 20,000 shares in the last quarter. Institutional investors own 35.04% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. JMP Securities reduced their target price on Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating on the stock in a report on Friday, July 26th. Piper Sandler reduced their price objective on shares of Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Finally, Stifel Nicolaus decreased their target price on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cue Biopharma presently has a consensus rating of “Buy” and a consensus price target of $5.00.

Cue Biopharma Trading Up 49.6 %

Shares of CUE opened at $0.68 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.06 and a current ratio of 2.06. Cue Biopharma, Inc. has a 52-week low of $0.45 and a 52-week high of $3.25. The firm has a market cap of $33.05 million, a price-to-earnings ratio of -0.64 and a beta of 1.96. The business’s fifty day moving average is $0.66 and its 200-day moving average is $1.25.

Cue Biopharma (NASDAQ:CUE) last released its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The firm had revenue of $2.66 million for the quarter, compared to analysts’ expectations of $1.12 million. Cue Biopharma had a negative return on equity of 142.93% and a negative net margin of 566.02%. During the same quarter in the previous year, the business posted ($0.29) earnings per share. Equities analysts anticipate that Cue Biopharma, Inc. will post -0.87 EPS for the current fiscal year.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.